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Structural Determinants of CDK4 Inhibition and
Design of Selective ATP Competitive Inhibitors
(G1 phase), CDK2/cyclin A and CDK2/cyclin E (G1 and S
phases), and CDK1/cyclin B (G2/M phases). The primary
strategy for CDK inhibition has been to develop small
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Mokdad Mezna, Mark Thomas, Gavin Wood, molecules that compete with ATP for binding to the
kinase. However, an alternative approach currently be-David P. Lane, and Peter M. Fischer
Cyclacel Limited ing investigated is to block recruitment of macromolecu-
lar substrates to the complex [5]. While there are numer-James Lindsay Place
Dundee Technopole ous examples of very potent ATP competitive inhibitors
of CDK2 and CDK4 [6–8], very few compounds haveDundee DD1 5JJ
United Kingdom progressed past the preclinical stage [9]. Hence, there
remains tremendous scope for further development of
new classes of CDK inhibitors, especially those that
target the individual kinase isoforms specifically. Selec-Summary
tive inhibitors might be expected to be generally less
cytotoxic and perhaps to exhibit a better side effectA number of selective inhibitors of the CDK4/cyclin
profile. CDK4/cyclin D1 has been demonstrated to playD1 complex have been reported recently. Due to the
critical roles during initiation of cell division in quiescentabsence of an experimental CDK4 structure, the ligand
cells (G0/G1 transition) and cell cycle commitment atand protein determinants contributing to CDK4 selec-
the restriction point in G1. Furthermore, CDK4 and CDK6tivity are poorly understood at present. Here, we report
are frequently direct or indirect targets of genetic alter-the use of computational methods to elucidate the
ations in cancer and are amplified or overexpressed incharacteristics of selectivity and to derive the struc-
a variety of tumors [10]. Cyclin D-dependent kinasestural basis for specific, high-affinity binding of inhibi-
are therefore thought to represents viable targets fortors to the CDK4 active site. From these data, the
antitumor therapy, as kinase inhibition would preventhypothesis emerged that appropriate incorporation of
cell proliferation via maintenance of hypophosphory-an ionizable function into a CDK2 inhibitor results in
lated pRb, which remains complexed with E2F1/DP1,more favorable binding to CDK4. This knowledge was
thereby preventing transcription of genes necessary forapplied to the design of compounds in the otherwise
the progression into the S phase of the cell cycle [11–13].CDK2-selective 2-anilino-4-(thiazol-5-yl)pyrimidine
There have been numerous reports of ATP-competi-pharmacophore that are potent and highly selective
tive compounds that bind selectively to CDK4 and at-ATP antagonists of CDK4/cyclin D1. The findings of
tempts at optimizing their binding and specificity forthis study also have significant implications in the de-
individual kinase isoforms by using structure-based de-sign of CDK4 mimic structures based on CDK2.
sign methods [14–21]. However, there has been little
discussion of the factors, from both the inhibitor and
Introduction protein perspectives, contributing to CDK4 potency and
selectivity. Here, we report a comprehensive study of
The cyclin-dependent kinases (CDKs) are key regulators known selective inhibitors of CDK4 and describe the
of progression through the various stages of the eukary- structural basis for their preferential inhibition over
otic cell cycle [1, 2]. It has been shown that overexpres- CDK2. We have constructed a homology model of CDK4
sion and/or loss of function of key proteins implicated and used this model in order to dock structures of pub-
in the chain of events upstream and downstream of the lished inhibitors. The structural determinants for CDK4
CDKs leads to tumorigenesis and neoplastic transfor- inhibition observed from these calculations were then
mation [3]. This includes the cyclins (positive regulatory applied in order to guide the tailoring of the otherwise
subunits), the natural inhibitory proteins, p16/p19INK4, CDK2-selective 2-anilino-4-(thiazol-5-yl)pyrimidine phar-
p21WAF1, and p27KIP1, as well as the downstream targets macophore [22] to produce the first compounds in this
of CDK phosphorylation, i.e. the retinoblastoma protein series with CDK4/cyclin D1 selectivity.
(pRb) and the E2F family of transcription factors. In each
case, pharmacological inhibition of CDK activity should
lead to restoration of the cell cycle checkpoints and Results and Discussion
potentially trigger cell death via apoptosis [4]. It can
thus be seen that these enzymes represent interesting Generation and Validation of the CDK4
pharmaceutical targets, since tumors arising from a Homology Structure
number of different gene mutations could be treated by To date, there have been a number of CDK inhibitory
using kinase inhibitors specific for the CDKs. While at compounds described that bind preferentially to CDK4;
present at least nine CDK isoforms have been identified however, no significant progress in determining the fea-
and characterized, the main focus of CDK-based cancer tures required for selectivity toward CDK4 has been
therapy to date has been on CDK4 and CDK6/cyclin D reported. A major reason for this lack of insight has
been the paucity of structural information for this CDK
isoform. In contrast, there is a plethora of structural data*Correspondence: cmcinnes@cyclacel.com
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Figure 1. Homology Model of CDK4 and Docking of a Selective Inhibitor
(A) Ribbon diagram [29] for the homology structure generated for CDK4 based on sequence comparisons with the X-ray structures of CDK2
and CDK6. This figure illustrates the topology of protein kinase domains.
(B) Superposition of the models of Fascaplysin within the ATP binding sites of CDK2 and CDK4 generated by docking with Affinity (Insight2000,
Accelrys). The CDK2 docked ligand is colored with green carbon atoms, whereas the CDK4 ligand is in brown. Only the backbone ribbon of
CDK4 is shown along with the major residues differing in the two proteins. F80CDK2 and the hinge region H bonds are shown as reference
points. The position of E144CDK4 is induced by electrostatic interaction with the ligand.
for CDK2, as it has been crystallized successfully in correct and demonstrate its utility for further calcula-
tions.many forms, including monomeric and cyclin A-acti-
vated forms in free and inhibitor bound complexes. Until Based on analysis of the nature and sequence of the
residues lining the ATP binding pocket, it was possiblenow, two approaches have been used to obtain struc-
tural information and to generate binding modes for to determine the specific residues and side chains that
differ in the CDK4 structure with respect to CDK2 andCDK4 inhibitory molecules. These include (1) structures
derived from sequence homology with other CDKs to identify the interactions that could be exploited in the
design of selective compounds. This information could[20, 21] and (2) crystallization of monomeric CDK2,
where the residues differing in the ATP binding pocket be used in two ways, both in the enhancement of CDK4
selectivity and in the engineering of molecules with re-were replaced with the corresponding residues of the
CDK4 active site [23]. We have employed the homology duced binding to CDK4 and higher specificity for CDK2.
The residues comprising the ATP cleft of both CDK2modeling approach in conjunction with automated flexi-
ble docking methods to generate a set of binding and CDK4 are compared in Table 1. As can be seen,
the key differences concern residues T102CDK4 (foundhypotheses for the ligand-CDK4 complexes of a number
of published inhibitors. on the CDK “specificity surface”) and E144CDK4 (which
contact the phosphates of ATP [CDK2 analogy]). TheThe homology structure of CDK4 in the present study
was generated by using CDK2 and CDK6 as template other changes include the H95CDK4 and V96CDK4 replace-
ments for the hinge region H bonding-interacting resi-structures, since there are differing regions in both pro-
teins that possess high sequence identity with CDK4 dues. As these residues provide contacts through the
backbone, they would not be expected to impact inhibi-(Figure 1A). Before its use as the basis for further docking
simulations with CDK4-selective compounds, the model tor binding significantly. The composition of the two
binding pockets thus differs due to the nonconservativewas validated though docking of 4-[4-(2,4-dimethyl-thia-
zol-5-yl)pyrimidin-2-ylamino]phenol, a compound that changes in key ATP- and inhibitor-contacting residues.
is approximately equipotent against CDK2 and CDK4
[24]. The poses obtained for this inhibitor were shown Molecular Basis for CDK4 Selectivity of Published
ATP Inhibitor Structuresto be almost identical in the two ATP binding sites (with
only slight differences in the positioning of the hydroxy- As is summarized in Table 2, several compounds that
exhibit preferential binding to CDK4 over CDK2 haveanilino ring). This similarity was also confirmed by com-
parison of the energetics of binding, which correlate been described in the literature to date. These include
fascaplysin [20], NSC625987 [19], PD0183812 [14, 25],well with the equipotent IC50’s of this compound against
CDK2/A and CDK4/D1. In addition, the CDK2 docked and the urea-based inhibitors reported recently [17, 18,
23]. In order to determine the molecular basis for thestructure overlaid closely with the crystal structure [24].
These results therefore confirmed that the model was selectivity of these compounds in terms of their interac-
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Table 1. Comparison of the ATP-Contacting Residues in CDK2 and CDK4
10 18 31 64 80 81 82 83 85 86 89 131 134 144 145
CDK2 Ile Val Ala Val Phe Glu Phe Leu Gln Asp Lys Gln Leu Ala Asp
Ile Val Ala Val Phe Glu His Val Gln Asp Thr Glu Leu Ala Asp
CDK4 12 20 33 77 93 94 95 96 98 99 102 144 147 157 158
tions with the residues comprising the ATP binding jects slightly further into the base of the ATP cleft and
hence makes more complementary van der Waals con-pocket, the structure of each was used in molecular
docking experiments with the X-ray structure of CDK2 tacts with V18CDK2, F80CDK2, and L134CDK2, which is re-
flected in the more favorable vdW interaction energyand with the model structure of CDK4. The first com-
pound studied was the natural product fascaplysin, (Table 2). The contribution of the Coulombic term to the
enthalpy of binding, on the other hand, was strikinglywhich was recently described and shown to inhibit
CDK4/D1 with an IC50 of 0.35 M, without appreciable different between CDK2 and CDK4 (28 versus 60
kcal/mol, respectively) and resulted in a much more fa-activity on CDK2/E [20]. The structural basis for selectiv-
ity of this inhibitor was not immediately apparent from vorable energy for binding to CDK4 (86 kcal/mol more
favorable). The difference in nonbonded energies corre-examination of its docked poses in CDK2 and CDK4.
Fascaplysin, which contains a quaternary nitrogen at lates well with the observed potency differences (fas-
caplysin is at least 100-fold more active against CDK4)the intersection of two of its aromatic rings, binds in a
similar conformation in both cases with the lactam NH and examination of the catalytic sites of both enzymes
explains the structural basis for the variation. In CDK4,and carbonyl groups forming a donor-acceptor hydro-
gen bond pair to the hinge region (L83CDK2 [V96CDK4]) as an acidic residue (E144) replaces Q131CDK2, whereas a
neutral residue (T102CDK4) is substituted for the positivelyshown in Figure 1B. Such an interaction involving the
backbone connecting the N- and C-terminal kinase do- charged K89CDK2. These differences lead to a two-unit
increase in the formal charge of the ATP binding pocketmain lobes is observed with all CDK2 inhibitors and
many other kinase ATP antagonists. Relative to the of CDK2 relative to CDK4 and explain the more favorable
electrostatic energy with the latter kinase. The quater-CDK4 binding mode, the CDK2-docked structure pro-
Table 2. In Vitro Activity, Calculated pKa, and Energetic Data for Reported CDK4-Selective Inhibitors
Inhibitor Interaction Energy (kcal/mol)
CDK
Number Name Isoform IC50 (m) pKa (calculated) Total van der Waals Coulombic
1 Fascaplysin 4 0.35 – 88.1 28.6 60.1
2 50 1.6 30.1 28.5
2 PD0183812 4 0.008 7 115.3 77 38.3
2 0.165 30.9 5.5 36.4
3 NSC625987 4 0.2 0.5 31.4 28.6 4.6
2 100 – – –
4 Pyrazol-3-yl urea 4M2 1.6 10.3 32.1 30.5 1.6
4 0.2 54.2 33.8 20.4
2 25 28.8 29 0.2
5 Pyridin-2-yl urea 4M2 0.051 – 26.5 21.8 4.7
2 0.096 41.8 32.2 9.6
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Figure 2. Comparison of the Interactions of PD013812 with CDK2 and CDK4 Based on their Affinity-Modeled Structures
Residues of the ATP binding pocket differing and thus contributing to CDK4 (right) selectivity are labeled. The CDK2 (left) pose is more
compact as a result of a steric clash with K89.
nary nitrogen of fascaplysin is in close proximity to that observed with CDK2. As observed with fascaplysin,
examination of the ligand-protein nonbonded energiesE144CDK4, resulting in the increased contribution to the
Coulombic term. Additionally, the proximity of the ligand revealed significantly more favorable binding free energ-
ies with CDK4 (115 kcal/mol versus 31 for CDK2),quaternary N to K89CDK2 leads to less favorable binding
to CDK2. Interestingly, the steric constraint of the larger mostly as a result of the additional electrostatic contri-
bution from the charged nitrogen to E144CDK4 (Table 2).K89CDK2 side chain (salt bridged to D86CDK2) results in
contacts with the lipophilic rings of fascaplysin and also Again the role of K89CDK2 results in more complementary
contacts of the inhibitor with the interior of the cleft;in better complementarity with the lipophilic part of the
cleft relative to CDK4 (as shown by the more favorable however, it is also more compact and folds up on itself
(Figure 2). This advantage is offset in the CDK4 contextvdW interaction energy; Table 2); however, this in turn
results in weaker H bonding with the CDK2 hinge region by a more extended conformation of the ligand and
resulting contacts with T102CDK4 replacing K89CDK2, lead-(as shown by Ludi H bonding scores of 62 for CDK2
versus 78 for CDK4). The combination of less-optimal ing to more favorable vdW interaction energies with
CDK4 as a whole. In addition, for the CDK2 bound inhibi-H bonds and unfavorable electrostatic interactions thus
offsets the increase in vdW energy and results in the two tor, the observed hinge region H bonds are more optimal
(to Leu83CDK2) than those made to the correspondingorders of magnitude decrease in potency of fascaplysin
against CDK2 compared to CDK4. As D86CDK2 (D99CDK4) backbone atoms of V96CDK4 (as evidenced by the H bond
Ludi complementarity score of 349 versus 279). This isis invariant between the two kinases, it makes equal,
although important, contacts in both cases. Although a probably a consequence of the steric constraint of
K89CDK2 inducing a compacting of the inhibitor and wedg-CDK2-based homology model of CDK4 was presented
in the original report on fascaplysin [20], no mention ing it further into the cleft. The advantage provided by
the increase in H bonding complementarity is counteredwas made of the structural basis for the observed CDK
selectivity. Fascaplysin was also reported in that study by the charge-charge repulsion of the quaternary nitro-
gen, resulting in the observed selectivity of PD0183812.to have a 10-fold lower potency against CDK6. This
result is in line with the above discussion, as the residue As additional evidence for the contribution of the charge
to CDK4 binding of the series of compounds reportedin CDK6 corresponding to E144CDK4 is Q149 and thus
identical to CDK2 in this position. [14], only those containing a positively charged N were
selective for CDK4.The highly selective compound, PD0183812 (20-fold
selective for CDK4) [14], was subsequently modeled into The CDK4-selective 10H-acridine-9-thione NSC625987
was also modeled on a comparative basis with the ATPthe binding sites of the CDK4 and CDK2 models. The
correctness of the docked CDK2 complex was ascer- clefts of both CDK isoforms (Figure 3). This compound
contains three fused aromatic rings and was reportedtained by comparison with the described interactions
of a compound closely related to PD0183812 with CDK2 to have at least a 500-fold selectivity for CDK4 [19].
While this inhibitor possesses an ionizable N, its pKa is[14]. PD0183812 possesses at least one ionizable nitro-
gen that is potentially protonated at physiological pH, well below neutral pH (calculated pKa 0.5). The com-
pound is therefore essentially uncharged under physio-and the calculated pKa value for the piperidine N was
found to be 7.0. This suggests that this molecule would logical conditions. The selectivity of NSC625987 thus
mostly results from the differing contacts and side chainbe appreciably protonated under the conditions of the
assay. Flexible docking of the protonated inhibitor into orientations in CDK4. Molecular docking of NSC645787
with CDK2 did not result in a binding mode consistentthe CDK4 active site again generated a similar pose to
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the complex structure of the CDK4-specific bisarylurea
compounds described (Table 2). Of the inhibitors de-
scribed, those that bind preferentially to CDK4 again
contain protonated Ns, whereas those with little or no
selectivity do not contain this postulated determinant.
Despite the structural difference and the resulting effect
on the structure-activity relationship, no mention was
made of this feature, and few other details contributing
to CDK4 selectivity were discussed. To test our hypothe-
sis regarding CDK4 selectivity depending on the pres-
ence of appropriate cationic groups in the inhibitors,
further energetic calculations were performed on the
relevant crystal structures deposited in the protein data-
bank, in conjunction with docking calculations to gener-
ate structures not generated or disclosed. Two com-
pounds were examined that were reported as selective
and nonselective inhibitors of CDK4 with respect to
CDK2. The first (4, Table 2) was a pyrazol-3-yl urea
(CDK4 selective) containing a charged group, and the
second was a pyridin-2-yl urea (5, Table 2; equipotent)
without the latter functionality. The complex of 4 with
the CDK4M2, in which the residues of the CDK4 ATP
pocket were placed in the CDK2 frame, was deposited
in the protein databank. To determine the molecular
basis of selectivity, this compound was docked withFigure 3. The Modeled CDK4 Binding Mode of NSC625987 Gener-
CDK2. Calculation of the intermolecular inhibitor-CDKated by Molecular Docking
interaction energies surprisingly did not show a markedThe differing side chains of CDK2 are labeled in addition to the
difference between the CDK2 and CDK4 complexes ascorresponding side chains and backbone atoms of CDK4. The
smaller V96 (partial brown) and T102 residues of CDK4 result in had been observed with the ligands previously dis-
greater flexibility of the hinge region and more volume in the ATP cussed, even though 4 would have a formal charge of1
binding site, allowing NSC625987 to bind. under the assay conditions (Table 2). Further examina-
tion of the residues of the CDK4M2 construct revealed
that not all of the variations between the two CDK iso-
with known determinants of CDK inhibitor binding. The forms, particularly the Q131E exchange, had been ac-
modeled pose with CDK4, however, was suggestive of counted for in this mimic protein. To examine the effects
CDK inhibition, with an appropriate H bond from the of the E144CDK4 residue present in place of Q131 in CDK2,
ligand NH to the V96CDK4 carbonyl (Figure 3). The obser- the latter was replaced with a Glu residue in the context
vation that this inhibitor is not predicted to bind with of the mimic protein and the interaction energies were
known kinase inhibitory contacts is consistent with its recalculated. The results showed that the nonbonded
inactivity toward CDK2. The lack of binding most proba- energies were now considerably more favorable, the
bly results from its inability to make effective H bonds total increasing from 32 to 54 kcal/mol, mainly due
to the backbone of CDK2. The constraint imposed by to the Coulombic contribution. This result confirms that
the side chain of K89CDK2 in conjunction with the more E144CDK4 provides a considerable proportion of the bind-
bulky phenyl ring (F82CDK2) in the CDK2 binding pocket ing free energy for CDK4 inhibitors and that interaction
(H95CDK4) displaces these contacts and precludes overall with this residue should be accounted for in the design
complementary interactions with the ATP cleft. The of compounds that are selective for this kinase. Activity
larger volume and additional flexibility of the backbone testing of the CDK4M2 protein did indeed show that the
(due to the smaller V96CDK4 side chain) in the CDK4 active inhibitors were about 10-fold less potent on the CDK4
site enables high-affinity binding of NSC625987. mimic than against the native CDK4/cyclin D1 complex.
A recent study by Banyu Tsukuba/Merck described These results suggest that this potency difference could
the structure-based design of CDK4 selective inhibitors be reduced by incorporation of the Q131E mutation
by using several approaches [17, 18, 23]. A de novo into the mimic protein and that this construct would
design algorithm was used to identify ATP-competitive give a more accurate representation of the native CDK4
molecules, and this was followed by design through the binding mode.
use of a homology structure. This group were also the As an additional validation of the CDK4 homology
first to describe a mutagenesis strategy whereby CDK2 structure generated for our present study, the nonselec-
was used as a scaffold, and the differing residues in the tive compound 5 (Table 2) was docked into CDK4 and
ATP binding site were replaced with the corresponding the resulting binding mode compared with that found
residues of CDK4. This construct was validated by using in the CDK4M2 crystal structure complex. It was found
an in vitro kinase assay to demonstrate that while CDK4- that very close overlays were obtained between the pose
selective compounds were less potent against the CDK4 observed in the CDK4M2 and those for the inhibitor in
mimic CDK2 (CDK4M2), the rank order of selectivity was complex with the model structure. In addition, calcula-
tion of the nonbonded energies in each case (CDK2,preserved. This scaffold was then used to determine
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CDK4M2, and CDK4 model complexes) showed that CDK4 activity, while its CDK2 inhibition is increased by
only 2-fold. Of the selective inhibitors, compound 10,these were comparable and therefore consistent with
the similar IC50’s for this inhibitor against both CDK2 and which contains a piperazine ring, was the most selective
with a 30-fold higher potency in the CDK4/D1 kinaseCDK4. This result provides additional validation that a
general correlation of this nature can be made and that assay. Inhibitors containing methylpiperazine (7) and hy-
droxyethylpiperazine (8) also exhibited CDK4 selectivity;the CDK4 model structure provides a structural rationale
for CDK4 selectivity. however, they did so to a lesser degree.
To provide further conformation of the CDK4 selectiv-
ity hypothesis, the pKa value was calculated for the ioniz-
Structural Basis for CDK4 Selectivityable N of the CDK inhibitor flavopiridol (Table 2, 6), which
of Anilinopyrimidinespreferentially inhibits CDK4 over CDK2 (3- to 5-fold) [26].
To date, several hundred compounds in the anilinopyri-The resulting value of 8.5 again demonstrates that this
midine series have been synthesized; analogs 1, 2, 6,feature contributes to the selectivity profile of CDK4
7, 8, and 10, however, are the first examples of CDK4-inhibitors.
selective derivatives in this series. The observed prefer-
ential binding of these compounds to CDK4 thus con-
firmed the initial design hypothesis that appropriateDesign of CDK4-Selective Compounds Based
on the 2-anilino-4-(thiazol-5-yl)pyrimidine System introduction of positively charged groups into the inhibi-
tor results in increased CDK4 selectivity. As a furtherWe have shown recently that potent and selective ATP-
competitive CDK inhibitor compounds can be generated test of the hypothesis, the pKa values for the ionizable
nitrogens in each of the inhibitors were calculated (Tablefrom the 2-anilino-4-(thiazol-5-yl)pyrimidine template
[22, 24]. In our hands, this pharmacophore to date has 3). As can be seen from this table, all the CDK4-selective
compounds have a pKa of seven or greater and, thus,yielded predominantly CDK2-selective inhibitors, some
of them with nanomolar or subnanomolar potency. Fur- would be partially or fully charged at the pH conditions in
which the assay was performed. There is no correlation,thermore, we have crystallized several analogs in com-
plex with CDK2 and therefore have a good under- however, between the basisity of the nitrogen and the
extent of observed selectivity for CDK4, therefore sug-standing of the structure-activity relationship of the
pharmacophore with respect to CDK2. The main deter- gesting that other determinants contribute to the selec-
tivity. In order to determine all of the factors contributingminants for high-potency binding include the H bond
donor/acceptor pair involving the bridging anilino NH to binding of these compounds to both CDK2 and CDK4,
docking with the homology structure and modeling cal-and the pyrimidine N6 to the hinge region of CDK2; a
nonpolar contact from the thiazol-4-yl methyl group with culations in the context of the available CDK2-complex
crystal structures were carried out with compounds 1, 5,F80, H bonding contacts from polar thiazole substitu-
ents with Q131, and van der Waals and H bonds from 6, and 10. For inhibitor 1, containing a meta-aminomethyl
group on the aniline ring, the docked structure showedthe pyrimidine and aniline aromatic rings (V18, D86, K89,
and L134). The aniline ring is in the position correspond- that it forms the expected binding mode with CDK4 and
has similar interaction energies to those observed foring to the charged group determined in this study to
contribute to CDK4 selectivity. In order to probe the other potent CDK4 inhibitors. Modeling of the amino-
methyl interactions for compound 1 with CDK2 indicatesidentified CDK4 selectivity determinants in the context
of the aminopyrimidine system, compounds that incor- that much less favorable interaction energies are ob-
tained compared to CDK4, resulting from Coulombicporated ionizable groups on the anilino ring were de-
signed and synthesized. Table 3 shows the structures and van der Waals repulsion with K89CDK2. Comparison
of the binding of inhibitors 5 and 6 to the ATP site ofof several compounds incorporating anilines substituted
with amine, methylamine, morpholine, and various pi- both enzymes is significant in this case, given that they
only differ by the NH of the piperazine ring (morpholineperazines. In addition, the pKas for the primary ionizable
groups in these substituents was calculated. As nega- in 5) and is significant given that 6 is selective for CDK4
(Table 3). Energetic analysis suggests as before thattive controls, potential inhibitors incorporating a mor-
pholine ring (5) (isosteric with piperazine) and an acet- the positively charged NH group of the piperazine ring
contributes extensively to CDK4 binding through inter-ylated primary amino group (3) were synthesized.
Neither of these compounds has a substituent capable action with E144CDK4 and D99CDK4 and, thus, is consistent
with the selectivity hypothesis. The highly CDK4 selec-of forming ion-pair interactions with E144CDK4 (noncon-
served with CDK2) and D99CDK4 (conserved with CDK2). tive inhibitor 10, having an IC50 of 7 nM against CDK4/
D1, was docked into the ATP binding site of CDK4.Furthermore, the benzenediamine compound 4, whose
aniline NH2 function is positively charged only below pH The resulting binding mode very closely represents the
structure observed with 6 and overlay of the inhibitor5, was analyzed. Testing of the compounds in Table 3
in both CDK2/E and CDK4/D1 kinase assays revealed with the crystallographically derived CDK2 complex of
9 (Figure 4) indicates the electrostatic interaction withthat only the compounds with a function associated with
the aniline ring that is protonated at pH 7 exhibited E144CDK4 results in the piperazine ring moving signifi-
cantly toward the acidic residues. As can be seen, theselectivity for CDK4. In contrast, all of the inhibitors
without this characteristic were partially selective for intermolecular contacts of thiazole and pyrimidine rings
match closely in both cases; however, interactions ofCDK2. In particular, comparison of compounds 5 and
6, which differ only by the oxygen-to-nitrogen replace- the saturated ring result in its displacement (and that of
the aniline) with respect to the position of the corre-ment in the saturated ring, demonstrates that the pipera-
zine inhibitor has a more than 20-fold enhancement in sponding rings of 9 in the CDK2 active site. Overall,
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Table 3. In Vitro Potencies, pKa, and Selectivity Ratios for Aminopyrimidine Compounds
Structure
Kinase Inhibition (m)
Number R1 R2 R3 pKa CDK4/D1 CDK2/E CDK4 Selectivity (Fold)
1 NHMe H CH2NH2 9.6 0.23 0.41 1.8
2 NHEt H CH2NH2 9.6 0.11 0.33 3.0
3 NHMe H CH2NHAc  0.89 0.43 0.5
4 Me NH2 H 4.0 3.8 0.23 0.1
5 Me H 3.7 4.0 2.0 0.5
6 Me H 9.0 0.64 1.1 1.7
7 Me H 7.3 0.16 1.02 6.4
8 Me H 7.4 0.43 2.2 5.1
9 NH2 H 3.7 2.40 1.0 0.4
10 NHMe H 9.0 0.007 0.22 31.4
inhibitor 10 exhibits striking complementarity with the Very recent publications have detailed a pharmaco-
phore that has common structural features with theATP cleft and very favorable nonbonded energetics, in
line with the in vitro potency of this compound. The novel CDK4 selective compounds we have described
[15, 27]. This series of inhibitors contains a pyrimidinestructure also presents evidence for the increase in po-
tency of this compound relative to 6, which only differs derivatized with two aniline groups (Table 2, 7). All of
the compounds described contain a hydroxy-dimethy-in the thiazole substitution. The methylamino group on
the thiazole ring of 10 contributes hydrogen bonds to laminopropane function that has a calculated pKa of 8.7.
In the deposited CDK2-complex structures, the positionE158CDK4 and the piperazine ring additionally provides
vdW surface complementarity with the specificity sur- of the charged group is directly analogous to that ob-
served for the substituted piperazine groups in the inhib-face. These interactions most likely provide the majority
of the increase in affinity of this ligand. Analysis of the itors disclosed here. Several analogs are reported that
have varying levels of inhibition against CDK2 and CDK4.nonbonded energies for both compounds again corre-
lates well with in vitro potency. The structure of these inhibitors is consistent with the
selectivity hypothesis proposed here, since all of theThe docking experiments also provide insight into the
potency and selectivity of compounds 7 and 8, having compounds contain the same protonated group and are
between 5- and 20-fold selective for CDK4. Interestingly,methyl- and hydroxyethyl-substituted piperazines, re-
spectively. These two inhibitors have a less-basic pip- the compounds that are optimized for CDK4 binding
also undergo a similar relative increase in CDK2 activity.erazinyl nitrogen and, hence, would be expected to be
less selective for CDK4; however, the converse is true. This suggests that for these examples, the charged
functional group contributes extensively to the observedThe results suggest that the piperazine substituents pro-
vide an increase in potency through vdW contacts with selectivity, and additional interactions with residues
common to both kinases result in the increase in bindingthe C of R101CDK4. As discussed previously, the in-
creased selectivity of 7 and 8 is likely due to the steric to both CDKs.
consequence of the additional group adjacent to
K89CDK2, resulting in lower affinity for CDK2. The methyl- Significance
ated (7) and hydroxyethyl (8) piperazines would therefore
bind less potently to CDK2 and be more selective for We have performed an in-depth computational inves-
tigation into the pharmacophoric requirements forCDK4. The additional space provided by T102CDK4, in
comparison to K89CDK2, thus would enable these inhibi- selective inhibition of CDK4. The results obtained
demonstrate that two major determinants of CDK4-tors to bind with higher affinity to CDK4.
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(Accelrys, San Diego, CA). For the model construction, the CDK2
(1CKP, resolution 2.0 A˚) and CDK6 (1BLX, resolution 1.9 A˚) structures
were used. Sequence alignment of CDK4 with CDK2 was performed
by using the PAM 120 multiple scoring matrix with a dimension
block of 0.6, a high significance p value of 0.0001, a not significant
p value of 0.1 and a pairwise threshold of 60. By using a combination
of the two structures to generate coordinates for the regions that
had the highest identity in each kinase, a model structure for the
kinase domain was constructed. The strategy generally involved
using CDK2 to define the structurally conserved regions (SCRs)
from which the coordinates were subsequently transferred. This was
followed by loop construction where the non-SCRs were generated
from CDK2 and CDK6 and additionally by de novo building and
subsequent evaluation of the most realistic coordinates (in terms
of energetics of the loops and the exclusion of loops leading to
overlapping atoms). After loop building was completed for missing
coordinates, the raw coordinates were refined by using successive
rounds of end repair splice repairing with an omega force constant
of 50 and energy minimization (100 steps of steepest descent to a
derivative of 5). The model was then completed through a further
minimization and 1 ps of molecular dynamics to explore more fully
the conformational space of the loop regions. The final model struc-
ture was checked against databases of protein structures for bond
length and dihedral angle violations. The results indicated that these
as a whole were within acceptable limits with 80% of residues
having phi-psi plots within the allowed region in Ramachandran
space.
Molecular Modeling
The structure coordinates of the ternary complex of CDK2/cyclin
Figure 4. Comparison of Ligand Positions of Compounds 10 and 9 A/p27KIP1 were obtained from the RCSB (accession code 1JSU). CDK
For 9 (blue carbons, CDK2), the X-ray structure in complex with inhibitors were docked into the ATP site of the CDK2 X-ray crystal
CDK2/cyclin A was used, while for 10 (yellow carbons, CDK4), the structure or the CDK4 model structure by using the Affinity program
bound structure was predicted by affinity docking with CDK4. Elec- (Molecular Simulations, San Diego, CA). The binding site was de-
tron density for inhibitor 10 is displayed in light blue. The similarity fined as an 8 A˚ radius from the center of a ligand binding mode.
on the pyrimidine and thiazole functions is apparent in the two This molecular docking routine, which incorporates a full molecular
structures, while interactions of the piperazine with E144 results in mechanics approach, allows for flexibility both in the ligand and in
significant movement and displacement of this ring in conjunction the side chains and backbone of the receptor (the positions of the
with the aniline.  carbon atoms were fixed during the simulation). The calculation
was performed by using the CVFF force field in a two-step process
with an implicitly derived solvation model and geometric H bond
restraints. For the initial phase of the calculation, the inhibitor wasspecific binding are as follows. (1) There is a require-
minimized into the ATP cleft by using a simple, nonbonded methodment for the geometrically appropriate presence of a where the Coulombic and van der Waals terms are scaled to zero
function in the inhibitor that is positively charged at and 0.1, respectively. The subsequent refinement phase involved
physiological pH. This functionality results in a more conformational sampling by using molecular dynamics calculated
over 5 ps in 100 fs stages, where the temperature was scaled fromfavorable Coulombic energy of interaction between
500 to 300 K. The calculation was completed by a final minimizationthe ATP cleft of CDK4 (D99CDK4, E144CDK4) and repulses
over 1000 steps using the Polak-Ribiere conjugate gradient method.the inhibitor from the active site of CDK2 through
The docked structures were ranked energetically (by using the inK89CDK2. (2) The incorporation of a bulky substituent in house developed programs Calsor and Calsorcont, values reported
the inhibitor that occupies the volume of the ATP site in kcal/mol) and by consistency of the nonbonded contacts with
proximal to K89CDK2 and D86CDK2. This group precludes known CDK and kinase interactions in order to determine the most
representative binding mode. While the values obtained for intermo-effective binding to CDK2 through steric hindrance
lecular interaction energies obtained using Affinity are not com-with these residues and, in some cases, results in
pletely accurate, they have been found in this study and in othersdisruption of effective H bonds to the hinge region of
to correlate with inhibitor potency when compared within a chemicalthe kinase. series. The absolute values should not necessarily be considered
The suitable incorporation of these determinants to reflect the actual binding constant.
into a known CDK2-selective molecule or into a non-
optimal CDK4 inhibitor should facilitate the develop- pKa Calculation
pKa values of the ionizable nitrogens for the CDK inhibitors werement of an inhibitor that binds with higher affinity and
calculated by using the ACD Labs (Toronto, Canada) pKa DB soft-preferentially to CDK4/cyclin D1, or alternatively, these
ware. ACD pKa DB is a program that calculates accurate acid-basefeatures could be used to modify nonselective low-
ionization constants (pKa values) at 25C and zero ionic strength inaffinity lead compounds to interact more favorably aqueous solutions and is reported to have a general accuracy
with this complex. of 0.2 pKa units.
Assay Screening, Protein Expression,Experimental Procedures
and X-Ray Crystallography
Kinase assays were performed according to the previously pub-Homology Model Construction
The homology model for CDK4 was generated by using the program lished procedure [22]. Protein expression, purification, and crystal-
lography were carried out as outlined [28].module Homology within the molecular modeling package InsightII
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Synthesis of Aminopyrimidine Analogs 2.64 (s, 3H, CH3), 3.54 (m, 2H, CH2), 4.11 (m, 2H, CH2), 7.14 (d, 1H,
A Typical Procedure for Preparation of 3-dimethylamino- J 	 6.0 Hz, pyrimidinyl-H), 7.22 (d, 1H, J 	 8.0 Hz, Ph-H), 7.45 (t,
1-(thiazol-5-yl)propenone 1H, J 	 8.0 Hz, Ph-H), 7.74 (d, 1H, J 	 8.0 Hz, Ph-H), 7.95 (s, 1H,
A solution of 3-chloropentane-2,4-dione (2.5 g, 19 mmol) in MeOH Ph-H), 8.53 (d, 1H, J 	 6.0 Hz, pyrimidinyl-H). MS (ESI) m/z 341.20
(10 mL) was treated with methyl thiourea (1.67 g, 19 mmol) and [MH] (C17H20N6S requires 340.45).
pyridine (1.5 mL). The mixture was stirred at room temperature for 3-[4-(2-Ethylamino-4-methyl-thiazol-5-yl)pyrimidin-
2 hr. Precipitated 1-(4-methyl-2-methylaminothiazol-5-yl)ethanone 2-yl-amino]benzylacetamide (3)
(2.10 g, 65%) was filtered, washed with Et2O, and dried. Mp 201C– Anal. RP-HPLC: tR 	 12.7 min (0%–60% MeCN, purity 95%). 1H-
203C. Anal. RP-HPLC (Vydac 218TP54 250
 4.6 mm column; linear NMR (CD3OD) : 1.17 (t, 3H, J 	 7.5 Hz, CH3), 1.98 (s, 3H, CH3), 2.51
gradient elution using H2O/MeCN containing 0.1% CF3COOH): tR 5.5 (s, 3H, CH3), 3.36 (q, 2H, J 	 7.1 Hz, CH2), 4.39 (s, 2H, CH2), 6.92 (m,
min (10%–70% MeCN, purity 100%). 1H-NMR (500 MHz, CDCl3):  2H, pyrimidinyl-H and Ph-H), 7.25 (t, 1H, J 	 7.6 Hz, Ph-H), 7.49 (m,
2.47 (s, 3H, CH3), 2.61 (s, 3H, CH3), 3.18 (s, 3H, CH3). 13C-NMR (DMSO- 1H, Ph-H), 7.79 (sbr, 1H, Ph-H), 8.25 (d, 1H, J 	 5.5 Hz, pyrimidinyl-
d6):  19.16, 30.05, 31.54, 49.28, 121.78, 158.54, 188.81. MS (ESI) H). MS (ESI) m/z 383.46 [MH] (C19H22N6OS requires 382.48).
m/z 170.87 (C7H10N2OS requires 170.23). This material (2.05 g, 12 N-[4-(2,4-Dimethyl-thiazol-5-yl)pyrimidin-2-yl]-benzene-1,
mmol) was suspended in N,N-dimethylformamide dimethylacetal
4-diamine (4)
(5.3 mL, 4.80 g, 40 mmol), and the mixture was heated at 120C
Mp. 206C–208C. 1H-NMR (DMSO-D6) : 2.59 (s, 3H, CH3), 2.62 (s,with stirring for 16 hr. After cooling, the reaction mixture was evap-
3H, CH3), 4.75 (brs, 2H, NH2), 6.51 (d, 2H, J 	 7.8Hz, Ph-H), 6.91 (d,orated to dryness. The residue was crystallized from EtOAc to afford
1H, J 	 4.9Hz, pyrimidinyl-H), 7.31 (d, 2H, J 	 7.8Hz, Ph-H), 8.383-dimethylamino-1-(4-methyl-2-methylaminothiazol-5-yl)propenone
(d, 1H, J 	 5.4Hz, pyrimidinyl-H), 9.11 (s, 1H, NH). MS (ESI) m/zas an orange solid (1.82 g, 67%): mp 209C–211C. Anal. RP-HPLC:
298.03 [MH] (C15H15N5S requires 297.38).tR 7.1 min (10%–70% MeCN, purity 100%). 1H-NMR (CDCl3):  2.55
[4-(2,4-Dimethyl-thiazol-5-yl)pyrimidin-2-yl](4-morpholin-(s, 3H, CH3), 2.94 (s, 3H, CH3), 3.41 (s, 6H, CH3), 5.30 (d, 1H, J 	 12.2
4-yl-phenyl)amine (5)Hz, CH), 7.64 (d, 1H, J 	 12.2 Hz, CH). 13C-NMR (DMSO-d6):  18.94,
Mp. 280C–282C. 1H-NMR (CDCl3) : 2.69 (s, 3H, CH3), 2.70 (s, 3H,31.41, 54.99, 94.32, 122.05, 152.96, 153.83, 169.41, 179.89. MS (ESI)
CH3), 3.14 (t, 4H, J 	 4.8 Hz, CH2), 3.72 (t, 4H, J 	 4.9 Hz, CH2), 6.89m/z 226.11 (MH]). Anal. (C10H15N3OS.MeOH) C, H, N.
(d, 1H, J 	 5.1 Hz, pyrimidinyl-H), 6.95 (d, 2H, J 	 8.8 Hz, Ph-H),3-Dimethylamino-1-(2-ethylamino-4-methylthiazol-
6.98(br. s, 1H, NH), 7.53 (d, 2H, J 	 9.1 Hz, Ph-H), 8.38 (d, 1H, J 	5-yl)propenone
Mp 204C–205C. Anal. RP-HPLC: tR 7.3 min (10%–70% MeCN, pu- 5.1 Hz, pyrimidinyl-H). MS (ESI) m/z 368.01 [MH] (C19H21N5OS
rity 100%). 1H-NMR (CDCl3):  1.25 (t, 3H, J 	 6.0 Hz, CH3), 2.49 (s, requires 367.47).
3H, CH3), 3.20 (s, 6H, CH3), 3.28 (m, 2H, CH2), 5.35 (d, 1H, J 	 11.5 [4-(2,4-Dimethyl-thiazol-5-yl)pyrimidin-2-yl](4-piperazin-
Hz, CH), 7.67 (d, 1H, J 	 11.5 Hz, CH). 13C-NMR (DMSO-d6):  14.92, 1-yl-phenyl)amine (6)
18.95, 31.41, 54.99, 94.34, 121.81, 152.92, 153.74, 168.49, 179.90. Mp. 301C–303C. 1H-NMR (CDCl3) : 2.62 (s, 3H, CH3), 2.63 (s, 3H,
MS (ESI) m/z 240.17 (MH)(C11H17N3OS requires 239.34). CH3), 2.99 (m, 4H, CH2), 3.06 (m, 4H, CH2), 6.81 (d, 1H, J 	 5.4 Hz,
3-Dimethylamino-1-(2,4-dimethylthiazol-5-yl)propenone pyrimidinyl-H), 6.89 (m, 3H, Ph-H, NH), 7.44 (m, 2H, Ph-H), 8.31
Mp 96C–98C. Anal. RP-HPLC: tR 7.1 min (10%–70% MeCN, purity (d, 1H, J 	 5.4 Hz, pyrimidinyl-H). MS (ESI) m/z 367.20 [MH]
100%). 1H-NMR (CDCl3):  2.66 (s, 6H, CH3), 2.70 (s, 6H, CH3), 5.37 (C19H22N6S requires 366.48).
(d, 1H, J 	 12.2 Hz, CH), 7.66 (d, 1H, J 	 12.2 Hz, CH). 13C-NMR [4-(2,4-Dimethyl-thiazol-5-yl)pyrimidin-2-yl][4-(4-methyl-
(DMSO-d6):  18.19, 19.52, 37.77, 45.19, 94.50, 134.01, 153.62, piperazin-1-yl)phenyl]amine (7)
154.38, 165.64, 179.93. MS (ESI) m/z 211.01 (MH). Anal. (C10H14 1H-NMR (CDCl3) : 2.37 (s, 3H, CH3), 2.61 (m, 4H, CH2), 2.69 (s, 3H,N2OS) C, H, N. CH3), 2.70 (s, 3H, CH3), 3.20 (m, 4H, CH2), 6.88 (d, 1H, J 	 5.1 Hz,General Procedure for Paration of N-phenyl-
pyrimidinyl-H), 6.94 (s, 1H, NH), 6.96 (d, 2H, J 	 8.8 Hz, Ph-H), 7.51guanidine Nitrates
(d, 2H, J 	 8.8 Hz, Ph-H), 8.38 (d, 1H, J 	 5.1 Hz, pyrimidinyl-H).To an ice-cooled mixture of the appropriate aniline (25 mmol) in
2-(4-{4-[4-(2,4-Dimethyl-thiazol-5-yl)pyrimidin-2-EtOH (6 mL) nitric acid (1.8 ml of 70% solution in H2O) was added
ylamino]phenyl}piperazin-1-yl)ethanol (8)dropwise with stirring. After complete addition, cyanamide (5 ml of
1H-NMR (CDCl3) : 2.55 (t, 2H, J 	 5.4 Hz, CH2), 2.62 (m, 10H, CH3 &50% solution in H2O) was added, and the mixture was heated at
CH2), 3.12 (t, 4H, J 	 4.9 Hz, CH2), 3.60 (t, 2H, J 	 5.4 Hz, CH2), 6.81100C for 16–18 hr under N2. After cooling to room temperature, it
(d, 1H, J 	 5.4 Hz, pyrimidinyl-H), 6.88 (m, 2H, Ph-H), 7.05 (br. s,was poured into excess Et2O and was basified with aq NaOH solu-
1H, NH), 7.45 (m, 2H, Ph-H), 8.30 (d, 1H, J 	 5.1 Hz, pyrimidinyl-H).tion. The ethereal layer was separated, and the aqueous phase was
MS (ESI) m/z 411.70 [MH] (C21H26N6OS requires 410.54).extracted with Et2O several times. The combined organic phases
were washed with brine, dried on MgSO4, filtered, and evaporated. [4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-
The resulting residue was purified by crystallization or flash chroma- (4-morpholin-4-yl-phenyl)-amine [9]
tography in appropriate mixtures of EtOAc/PE or EtOAc/MeOH. Mp. 300C–304C: 1H-NMR (DMSO-d6) : 2.46 (s, 3H, CH3), 3.07 (m,
General Procedure for Preparation of [4-(thiazol- 4H, CH2), 3.76 (m, 4H, CH2), 6.85 (d, 1H, J 	 5.3 Hz, pyrimidinyl-H),
5-yl)pyrimidin-2-yl]phenylamines 6.92 (m, 2H, Ph-H), 7.53 (br. s, 1H, NH), 7.67 (m, 2H, Ph-H), 8.30 (d,
A mixture of 3-dimethylamino-1-(thiazol-5-yl)propenone (1 equiv), 1H, J 	 5.4 Hz, pyrimidinyl-H), 9.25 (br. s, 1H, NH). MS (ESI) m/z
the appropriate N-phenyl-guanidine nitrate (2 equiv), and NaOH (1 369 [MH] (C18H20N6OS requires 368.5).
equiv) in 2-methoxyethanol were heated at 125C for 22 hr under [4-(2-Methylamino-4-methyl-thiazol-5-yl)pyrimidin-2-
N2. After cooling, the solvent was evaporated, and the residue was yl](4-piperazin-1-yl-phenyl)amine (10)
purified by flash chromatography with appropriate mixtures of Anal. RP-HPLC: tR 	 8.8 min (10%–70% MeCN, purity 95%). 1H-EtOAc/hexane as the eluant. Pure products were obtained following NMR (DMSO-d6) : 2.45 (3, 3H, CH3), 2.83 (t, 4H, J 	 5.9Hz, CH2),recrystallization.
2.85 (d, 3H, J 	 4.9Hz, CH2), 2.95 (t, 4H, J 	 4.9Hz, CH2), 6.81 (d,3-[4-(2-Methylamino-4-methyl-thiazol-5-yl)pyrimidin-2-yl-
1H, J 	 5.4Hz, pyrimidinyl-H), 6.85 (d, 2H, J 	 9.3Hz, Ph-H), 7.58amino-benzylacetamide (1)
(d, 2H, J 	 8.8Hz, Ph-H), 7.99 (m, 1H, NH), 8.26 (d, 1H, J 	 5.4Hz,Mp. 253C–255C. Anal. RP-HPLC: tR 	 11.3 min (10%–70% MeCN,
pyrimidinyl-H), 9.14 (brs, 1H). MS (ESI) m/z 382.06 [MH]purity 95%): 1H NMR (DMSO-D6):  1.86 (s, 3H, CH3), 2.46 (s, 3H,
(C19H23N7S requires 381.50).CH3), 2.85 (s, 2H, CH2), 3.09 (s, 3H, CH3), 6.82 (d, 1H, J 	 8.0 Hz,
ph-H), 6.88 (d, 1H, J 	 5.5 Hz, pyrimidinyl-H), 7.2 (t, 1H, J 	 8.0 Hz,
Ph-H), 7.60 (d, 1H, J 	 8.0 Hz, Ph-H), 7.73 (s, 1H, Ph-H), and 8.32
Acknowledgments(d, 1H, J 	 5.5 Hz, pyrimidinyl-H). MS (ESI) m/z 391.55 [MNa]
(C18H20N6OSNa requires 391.46).
The authors would like to thank Brian McClue and Richard Main3-[4-(2-Ethylamino-4-methyl-thiazol-5-yl)pyrimidin-2-yl-
for IT support, and Professor Malcolm Walkinshaw (University ofamino]benzylamine (2)
Edinburgh) and Dr. Howard Marriage (Cyclacel) for helpful discus-Mp. 290C–292C. Anal. RP-HPLC: tR 	 10.6 min (10%–70% MeCN,
purity 95%). 1H-NMR (DMSO-D6) : 1.31 (t, 3H, J 	 7.0 Hz, CH3), sions and proof reading of this manuscript.
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